Sage Therapeutics
SAGE

$7.90

4.08%

Market Cap: $475M

About: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Employees: 487

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 14 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

363% more call options, than puts

Call options by funds: $10.1M | Put options by funds: $2.18M

41% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 54

5% less funds holding

Funds holding: 200 [Q1] → 191 (-9) [Q2]

10.03% less ownership

Funds ownership: 98.91% [Q1] → 88.88% (-10.03%) [Q2]

22% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 41

48% less capital invested

Capital invested by funds: $1.12B [Q1] → $581M (-$534M) [Q2]

See Fund Rankings

Research analyst outlook

14 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

27%

upside

Avg. target

$19.29

144%

upside

High target

$52

558%

upside

14 analyst ratings

4 positive

29%

10 neutral

71%

0 negative

0%

Truist Securities Joon Lee 67% 1-year accuracy 30 / 45 met price target	65%upside $13	Hold Maintained	14 Aug 2024
JP Morgan Anupam Rama 42% 1-year accuracy 24 / 57 met price target	27%upside $10	Neutral Maintained	6 Aug 2024
HC Wainwright & Co. Douglas Tsao 56% 1-year accuracy 79 / 142 met price target	216%upside $25	Neutral Reiterated	2 Aug 2024
Piper Sandler Yasmeen Rahimi 48% 1-year accuracy 11 / 23 met price target	558%upside $52	Overweight Maintained	1 Aug 2024
TD Cowen Ritu Baral 67% 1-year accuracy 4 / 6 met price target	27%upside $10	Hold Downgraded	30 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 183 articles about SAGE published over the past 30 days

Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE

NEW YORK, NY / ACCESSWIRE / September 20, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=103980&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE

SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESSWIRE / September 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sage securities between April 12, 2021, and July 23, 2024, inclusive (the "Class Period").

SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc.(SAGE) Shareholders

NEW YORK , Sept. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action securities lawsuit.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc.(SAGE) Shareholders

Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action securities lawsuit.

Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE

Sage Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAGE

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=103889&wire=1 or contact Joseph E. Levi, Esq.

Sage Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAGE

Sage Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=103872&wire=1 or contact Joseph E. Levi, Esq.

Sage Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE

Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) should contact Levi & Korsinsky about pending Class Action - SAGE

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=103810&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) should contact Levi & Korsinsky about pending Class Action - SAGE

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06511, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sage securities between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE

See News Rankings